<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A retrospective analysis was performed on 76 consecutive elderly patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> aged 60 years or more (48 men, 28 women) </plain></SENT>
<SENT sid="1" pm="."><plain>Forty patients were 60-69 years old, 28 were 70-79 years old and 8 were &gt; or = 80 years old </plain></SENT>
<SENT sid="2" pm="."><plain>There were 55 patients with <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 13 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) and 8 AML from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were treated with the JALSG protocol, CAG regimen, or low-dose Ara-C regimen for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and DVP/M-CHOP protocol for ALL </plain></SENT>
<SENT sid="4" pm="."><plain>The complete remission (CR) rates were 52.7% (29 of 55) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 61.5% (8 of 13) in ALL, and 0% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The median CR durations were 226, 85, 0 days, and the median survivals were 204, 177, 99 days, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>CR rates were 65.3% for the JALSG protocol, 62.5% for the CAG regimen and 25.0% for low-dose Ara-C regimen </plain></SENT>
<SENT sid="7" pm="."><plain>According to age, CR was obtained 62.5% in patients aged 60-69 years and 33.3% in patients over 70 years old </plain></SENT>
<SENT sid="8" pm="."><plain>Our results indicated that patients aged 60-69 years should be treated with intensive chemotherapy </plain></SENT>
</text></document>